Novartis AG (NVS) Shares Sold by Motco
Motco cut its holdings in shares of Novartis AG (NYSE:NVS) by 2.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 90,770 shares of the company’s stock after selling 2,735 shares during the quarter. Motco’s holdings in Novartis were worth $7,621,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of NVS. Cetera Investment Advisers bought a new stake in shares of Novartis during the second quarter valued at approximately $241,000. Bartlett & Co. LLC boosted its position in shares of Novartis by 1.6% during the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after purchasing an additional 7,249 shares in the last quarter. Capital Bank & Trust Co boosted its position in shares of Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock valued at $11,865,000 after purchasing an additional 7,201 shares in the last quarter. Atlantic Trust Group LLC boosted its position in shares of Novartis by 54.2% during the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock valued at $6,218,000 after purchasing an additional 25,452 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of Novartis during the third quarter valued at approximately $1,245,000. 11.09% of the stock is currently owned by hedge funds and other institutional investors.
NVS has been the topic of several research reports. Zacks Investment Research upgraded Novartis from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Leerink Swann lifted their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research report on Tuesday, October 31st. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, UBS Group reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $85.32.
Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The business had revenue of $12.92 billion for the quarter, compared to the consensus estimate of $12.65 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. sell-side analysts anticipate that Novartis AG will post 5.36 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2018/02/08/novartis-ag-nvs-shares-sold-by-motco.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.